4CPS-042 Apremilast in psoriatic arthritis and psoriasis: a case report

BACKGROUND: Apremilast is an orally-active small molecule which inhibits phosphodiesterase-4 (PDE4). Clinical trials have demonstrated its efficacy and safety in psoriatic arthritis (PsA) and psoriasis (PsO). PsA is a chronic inflammatoryarthropathy that affects joints accompanied by inflammation of...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur J Hosp Pharm
Main Authors: Gonzalez, M Suarez, Melini, E Gomez, Ruiz, P Diaz, Gomez, MA Ocaña, Exposito, R Mesa, Delgado, A Montero, Alonso, J Merino
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Group 2018
Assuntos:
Section 4: Clinical pharmacy services
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535203/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.133
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares